-
Article
Open AccessErratum zu: Testung auf Mismatch-Reparatur-Defizienz und Mikrosatelliteninstabilität
-
Article
Open AccessTesting for deficient mismatch repair and microsatellite instability
Testing to detect mismatch repair deficiency (dMMR) and high-grade microsatellite instability (MSI-H) has become an integral part of the routine diagnostic workup for colorectal cancer (CRC). While MSI was ini...
-
Article
Open AccessTestung auf Mismatch-Reparatur-Defizienz und Mikrosatelliteninstabilität
Der Nachweis der Mismatch-Reparatur-Defizienz (dMMR) mit konsekutiver hochgradiger Mikrosatelliteninstabilität (MSI-H) ist inzwischen fester Bestandteil der Diagnostik des kolorektalen Karzinoms (KRK). Galt MS...
-
Article
Open AccessProficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue
Precision oncology based on specific molecular alterations requires precise and reliable detection of therapeutic targets in order to initiate the optimal treatment. In many European countries—including German...
-
Article
Erratum zu Mitteilungen der Deutschen Gesellschaft für Pathologie
-
Article
MSI testing
Based on new trial data regarding immune checkpoint inhibitors (ICIs), the detection of high-grade microsatellite instability (MSI-H) or underlying deficient mismatch repair protein (dMMR) is now becoming incr...
-
Article
Open AccessStatus quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing
With this external quality assessment (EQA) scheme, we aim to investigate the diagnostic performance of the currently available methods for the detection of ALK alterations in non-small cell lung cancer on a n...
-
Article
Qualitätssicherung in der dMMR- und MSI-Diagnostik
Mismatch-Repair-Defizienz (dMMR) und Mikrosatelliteninstabilität (MSI) haben nicht nur bei kolorektalen Karzinomen, sondern auch bei Karzinomen anderer Entitäten (Endometrium, Gallenwege, Pankreas) eine therap...
-
Article
MSI-Testung
Aufgrund neuer Studiendaten mit Immuncheckpoint-Inhibitoren (ICI) gewinnt der Nachweis einer hochgradigen Mikrosatelliteninstabilität (MSI-H) bzw. der zugrunde liegenden Mismatch-Repair-Protein-Defizienz (dMMR...
-
Article
Qualitätssicherung in der diagnostischen In-situ-Hybridisierung – Erfahrungen der QuIP
Die „Qualitätssicherung-Initiative Pathologie“ (QuIP) bietet den Pathologen die Möglichkeit, die methodischen Abläufe der immunhistologischen und molekularen Diagnostik ergebnisorientiert überprüfen und zertif...
-
Article
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial
Ki-67 has been clinically validated for risk assessment in breast cancer, but the analytical validation and cutpoint-definition remain a challenge. Intraclass correlation coefficients (ICCs) are a statistical ...
-
Chapter
Praktische Durchführung der ärztlichen Leichenschau – Aufgabenkomplexe
Die erste und wichtigste Aufgabe bei der ärztlichen Leichenschau ist die sichere Feststellung des eingetretenen Todes. Da der Arzt die Differentialdiagnose zu treffen hat, ob der Patient verstorben ist oder ob...
-
Chapter
Obduktionen
Die Obduktion, die innere Leichenuntersuchung, ist eine der für die Entwicklung der neuzeitlichen Medizin wegweisendsten Untersuchungsmethoden. Die anatomische Sektion entwickelte sich in den oberitalienischen...
-
Article
Open AccessRNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance
Rearrangements of the anaplastic lymphoma kinase (ALK) belong to the promising targets in the therapy of advanced non-small cell lung cancer (NSCLC) and are predominantly detected by immunohistochemistry (IHC)...
-
Article
Open AccessTreatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study
We evaluated treatment decisions and outcomes in a cohort of predominately Caucasian patients with EGFR mutation-positive (EGFR Mut+) non-small-cell lung cancer (NSCLC).
-
Article
EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial
The European Commision (EC) recently approved osimertinib for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR T790M mutations. Besides tissue-...
-
Article
Open AccessHER2 testing in gastric cancer: results of a German expert meeting
Valid HER2 testing is essential for optimal therapy of patients with HER2-positive gastric cancer and the correct use of first-line chemotherapy. While testing for HER2 status in breast cancer is routinely per...
-
Article
Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma
HER3 is a member of the epidermal growth factor family and was predominantly described as a negative prognostic factor in various solid tumors as well as in ovarian cancer. In this study, we investigated HER3 ...
-
Article
Open AccessTesting for ROS1 in non-small cell lung cancer: a review with recommendations
Rearrangements of the ROS1 gene occur in 1–2 % of non-small cell lung cancers (NSCLCs). Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the treatment of patients with adv...
-
Article
NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trial
With the approval of olaparib as monotherapy treatment in platinum-sensitive, relapsed high-grade serous ovarian cancer by the European Medical Agency (EMA), comprehensive genoty** of BRCA1 and BRCA2 in tumor t...
